It has been reported that the combined expression level of CD155 and TIGIT correlates with the prognosis of lung adenocarcinoma, gastric cancer, hepatocellular carcinoma, and head and neck squamous cell carcinoma [27–30]. Here, TIGIT is linked to hepatocellular carcinoma.